North York General Hospital (NYGH) is participating in the Canadian Treatments for COVID-19 (CATCO) study. The study, sponsored by Sunnybrook Research Institute and led by Dr. Srinivas Murthy at the national level, and Dr. Robert Fowler at the provincial level, is funded by the Canadian Institutes of Health Research. We are pleased to announce Dr. Anna Geagea is leading the trial at NYGH. The CATCO study is an open-label Randomized Controlled Trial (RCT), open to hospitalized COVID-19 positive patients.
CATCO is the Canadian arm of an unparalleled global collaboration coordinated by the World Health Organization to test four potential treatments for COVID-19. This multinational trial named SOLIDARITY is enrolling thousands of patients from around the world with the main goal to rapidly identify drugs to treat COVID-19 that may prove beneficial to patients.
The adaptive study protocol design will start off with testing lopinavir and ritonavir vs. supportive care. The plan is to extend it to allow testing of additional drugs, as more evidence becomes available.
For more information about the Canadian Arm of the SOLIDARITY trial visit: clinicaltrais.gov